SCHEMBL1798663

SCHEMBL1798663

COC(=O)c1ccc(CN2C(=O)CNC23CCN(C(=O)C2CCCCC2)CC3)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
NPC1 O15118 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
KDM4E B2RXH2 2/20 0.41
KMT2A Q03164 4/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CHKA P35790 1/20 0.39
MEN1 O00255 2/20 0.39
KDM1A O60341 1/20 0.38
MAOB P27338 1/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
EPHX2 P34913 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1797571 0.99 LMNA (0.44) LMNANPC1HTTRAB9AKDM4E
SCHEMBL1803525 0.97 NPC1 (0.44) LMNANPC1HTTRAB9AKDM4E
SCHEMBL5151635 0.89 KMT2A (0.42) KDM4EKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL5155543 0.88 L3MBTL1 (0.41) KDM4EKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL5155027 0.86 L3MBTL1 (0.44) KDM4EKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL1801345 0.81 MEN1 (0.45) LMNANPC1HTTRAB9AKDM4E
SCHEMBL12326127 0.79 NPC1 (0.47) LMNANPC1HTTRAB9AKMT2A
SCHEMBL3920891 0.79 LMNA (0.44) LMNANPC1HTTRAB9AKDM4E
SCHEMBL1803273 0.79 MEN1 (0.47) LMNANPC1HTTRAB9AKDM4E
SCHEMBL1801939 0.77 OPRD1 (0.47) LMNANPC1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US claimed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US disclosed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 LMNA 3374/4885NPC1 479/4885HTT 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.